Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Income from Continuing Operations (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Income from Continuing Operations for 4 consecutive years, with 69047000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Income from Continuing Operations rose 537.89% year-over-year to 69047000.0, compared with a TTM value of 86000.0 through Dec 2023, up 99.86%, and an annual FY2024 reading of 88853000.0, down 45937.82% over the prior year.
  • Income from Continuing Operations was 69047000.0 for Q4 2023 at Terns Pharmaceuticals, up from 29709000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 69047000.0 in Q4 2023 and bottomed at 29709000.0 in Q3 2023.
  • Average Income from Continuing Operations over 4 years is 9521375.0, with a median of 13544500.0 recorded in 2021.
  • Peak annual rise in Income from Continuing Operations hit 537.89% in 2023, while the deepest fall reached 76.63% in 2023.
  • Year by year, Income from Continuing Operations stood at 11109000.0 in 2020, then decreased by 29.0% to 14331000.0 in 2021, then fell by 10.03% to 15768000.0 in 2022, then skyrocketed by 537.89% to 69047000.0 in 2023.
  • Business Quant data shows Income from Continuing Operations for TERN at 69047000.0 in Q4 2023, 29709000.0 in Q3 2023, and 17896000.0 in Q2 2023.